z-logo
open-access-imgOpen Access
Demirtaş Erciyes-Mid urethral fibrin fixation technique (DE-MUFFT) for female stress urinary incontinence: A case series
Author(s) -
Türev Demirtaş,
Gökhan Sönmez,
Şevket Tolga Tombul,
Abdullah Demirtaş
Publication year - 2021
Publication title -
deneysel ve klinik tıp dergisi/journal of experimental and clinical medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.103
H-Index - 3
eISSN - 1309-4483
pISSN - 1309-5129
DOI - 10.52142/omujecm.38.4.53
Subject(s) - medicine , urinary incontinence , fibrin , urethral stricture , surgery , urology , urinary system , urethra , immunology
Factors including suburethral blood flow impairment, collagen deficiency, and the lack of tissue healing factors are known to play a role in stress urinary incontinence (SUI). Autologous fibrin (AF) appears to be a viable material for the treatment of SUI. The aim of this study was to present the initial clinical outcomes of a novel technique named “Demirtaş Erciyes-Mid Urethral Fibrin Fixation Technique (DE-MUFFT)” that involved the placement of AF material in the suburethral space instead of sling material (mesh). In this study, the clinical outcomes of five women with pure SUI who underwent the placement of AF material in the suburethral space were examined retrospectively. The complaint of urine leakage during physical exertion and patients’ quality of life were assessed using Incontinence Quality of Life Scale (I-QoL), International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), Incontinence Impact Questionnaire (IIQ-7), and 24-h pad test. Patient outcomes were evaluated preoperatively, at sixth week and third month postoperatively. Significant improvement was obtained in the quality-of-life tests and 24-h pad test. In all patients, the complaint of urine leakage disappeared almost completely. No adverse event or postoperative complication occurred in any of the patients. These results indicated that DE-MUFFT can be a promising procedure in the treatment of SUI due to its biocompatibility, minimally invasive nature, re-applicability, and cost-effectivity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here